The Trump administration said it will restart the risk adjustment payment program just weeks after suspending the payments; the first pill in a decade has been approved to treat pain caused by endometriosis; Eli Lilly executives said during the second quarter earnings call that the idea of importing drugs from abroad was “the wrong road to go down.”
The Trump administration said it will restart the risk adjustment payment program established under the Affordable Care Act that pays money to insurers who take on higher-risk patients. According to The New York Times, in reversing the decision, the administration is acknowledging that ending the payments could destabilize the insurance markets. The program was suspended July 8 after a court ruling. CMS’ decision had put $10.4 billion in risk adjustment transfer payments for the 2017 benefit year on hold. Payments will resume around October 22.
The first pill in a decade has been approved to treat pain caused by endometriosis, a common gynecologic disorder that affects approximately 1 in 10 women of reproductive age. It can cause severe pain and infertility. Testing of the drug found that it significantly reduced menstrual pain in 45% of women on the low dose and in 75% of women on the high dose, reported the AP. Side effects include hot flashes, headaches, and bone thinning. The drug will cost $845 every 4 weeks without insurance.
During Eli Lilly’s second quarter earnings call, executives said the idea of importing drugs from abroad was “the wrong road to go down.” The Hill reported that Lilly’s CEO said regulatory reforms would more successfully improve access to prescription drugs and keep prices affordable. He added that he is open to changing the Medicare drug rebate structure, under which drug companies negotiate rebates with insurers or pharmacy benefit managers.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More